Hussman Strategic Advisors Inc. Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Hussman Strategic Advisors Inc. cut its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 60.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 42,000 shares of the biopharmaceutical company's stock after selling 63,000 shares during the quarter. Hussman Strategic Advisors Inc.'s holdings in TG Therapeutics were worth $1,264,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in TGTX. Bleakley Financial Group LLC purchased a new position in TG Therapeutics in the fourth quarter worth $245,000. Castellan Group purchased a new stake in TG Therapeutics in the fourth quarter worth approximately $8,539,000. Oppenheimer & Co. Inc. purchased a new position in shares of TG Therapeutics during the third quarter worth approximately $759,000. Segall Bryant & Hamill LLC bought a new stake in shares of TG Therapeutics in the 3rd quarter worth approximately $1,225,000. Finally, Barclays PLC boosted its stake in shares of TG Therapeutics by 83.9% in the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after purchasing an additional 158,323 shares in the last quarter. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Trading Down 5.4 %

Shares of TGTX traded down $1.66 during trading hours on Monday, reaching $29.22. 1,751,068 shares of the company traded hands, compared to its average volume of 2,151,518. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $36.84. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company's fifty day moving average price is $31.07 and its two-hundred day moving average price is $27.84. The company has a market capitalization of $4.55 billion, a price-to-earnings ratio of -292.53 and a beta of 2.26.

Analysts Set New Price Targets

TGTX has been the subject of several analyst reports. JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a research report on Monday, November 25th. StockNews.com cut TG Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, January 31st. HC Wainwright reissued a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Wednesday, January 15th. The Goldman Sachs Group upped their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Finally, TD Cowen started coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a "buy" rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $40.67.

Insiders Place Their Bets

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares of the company's stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 10.50% of the stock is currently owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.